Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926868 · ClinicalTrials.gov registry record · Phase 2
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A Phase 2 study of Breast Neoplasms, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT06926868 is a Phase 2 study of Breast Neoplasms that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 500 participants, below the 564-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT06926868, a Phase 2 study of Breast Neoplasms, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Capecitabine
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
- DRUG Iza-bren
Study Locations (20)
California
- Helios Clinical Research - Cerritos
- Local Institution - 0307 - Cerritos
- Local Institution - 0308 - Cerritos
- Local Institution - 0309 - Cerritos
- Local Institution - 0311 - Long Beach
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- USC Norris Oncology/Hematology-Newport Beach - Newport Beach
- Local Institution - 0358 - Stanford
Illinois
- Local Institution - 0278 - Chicago
- Local Institution - 0280 - Chicago
- Decatur Memorial Hospital - Decatur
Colorado
- Local Institution - 0289 - Aurora
- Rocky Mountain Cancer Centers - Denver
Florida
- Local Institution - 0282 - Miami
- Local Institution - 0296 - Pembroke Pines
Georgia
- Local Institution - 0294 - Atlanta
- Northside Hospital - Atlanta
Arkansas
- Local Institution - 0303 - Hot Springs
Delaware
- Medical Oncology Hematology Consultants, PA - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2030-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06926868
The ClinicalTrials.gov registry entry for NCT06926868 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 564-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (11% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06926868 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Colorado.
Frequently Asked Questions
What is clinical trial NCT06926868 about?
NCT06926868 is a clinical study titled "A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)". The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for...
What is the current status of trial NCT06926868?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2025-09-11. Estimated completion is 2030-05-15.
What conditions does trial NCT06926868 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT06926868?
The interventions under investigation include: Carboplatin (DRUG), Capecitabine (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG), Iza-bren (DRUG).
Who is sponsoring clinical trial NCT06926868?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06926868 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.